GREY:IMVIF - Post by User
Comment by
pumpbuster2011on Nov 20, 2018 8:22am
77 Views
Post# 28998515
RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancer
RE:RE:DPX-Survivac as Monotherapy For Recurring Ovarian Cancerclinical marker present in apprx 30% of enrolled patients. Greater percentage (confidently said) in global patient population. Unreal..
They have a silver bullet.